Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-180-5 | CAS number: 79-14-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 21 July 1998 to 20 October 1998
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 84-2
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA health Effect Guidelines 40 CFR 799.9539
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
Test material
- Reference substance name:
- Glycollic acid
- EC Number:
- 201-180-5
- EC Name:
- Glycollic acid
- Cas Number:
- 79-14-1
- Molecular formula:
- C2H4O3
- IUPAC Name:
- 2-hydroxyacetic acid
- Details on test material:
- Glycolic acid 70% solution,
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- other: Crl:CD-1 (ICR)BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Inc., Raleigh, North Carolina.
- Age at study initiation: 43 days, 51 days when treated.
- Weight at study initiation: Males weighed 29.4-33.3g, females weighed 22.2-25.3g.
- Assigned to test groups randomly: yes, by computer generated random numbers
- Fasting period before study: no data
- Housing: 2-3 per cage during the quarantine period and individually during the study phase in standard wire mesh cages
- Diet: ad libitum
- Water : ad libitum
- Acclimation period: 8 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 degrees +or -1 degree
- Humidity (%): 50 +or - 10%
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12-hr light/dark cycle
Approximately 7 weeks old at time of dosing in the bodyweight range 29.4 to 33.3 g for males and 22.2 to 25.3 g for females
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: HPLC grade water.
- Justification for choice of solvent/vehicle: No data.
- Concentration of test material in vehicle: 42.5, 56.7, 85.0, 113.3, 170.0, 226.7 mg/ml administered by oral intubation in a
dose volume of 10 ml/kg.
- Amount of vehicle (if gavage or dermal): 10ml/kg. - Details on exposure:
- Acute exposure by oral intubation.
- Duration of treatment / exposure:
- single dosage
- Frequency of treatment:
- Single oral gavage administration
- Post exposure period:
- Negative controls and low/intermediate test groups: 5 male and 5 female animals were terminated 24 or 48 hours after dosing. Positive control animals were terminated 24 hours after dosing.
High dose treatment group: 5 male and 5 female animals were terminated 24 hours after dosing, the remaining animals were terminated after 48 hours.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 300 / 400, 600 / 800 and 1200 / 1600 mg/kg (males / females )
Basis:
actual ingested
male / female achieved dose levels
- No. of animals per sex per dose:
- 5 males and 5 females in low and intermediate dose groups (300/400 mg/kg bw and 600/800 mg/kg bw for males/females); 10 mice per sex in the control group and 15 males and 15 females in the high dose group (1200 or 1600 mg/kg bw for males and females respectively).
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Cyclophosphamide in Milli-Q water as solvent.
- Justification for choice of positive control(s): No data.
- Route of administration: Oral intubation.
- Doses / concentrations: 40mg/kg.
Examinations
- Tissues and cell types examined:
- Micronucleated polychromatic erythrocytes in mouse bone marrow and normochromatic erythrocytes
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: Based on a rangefinding study that identified clinical signs of toxicity.
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields): treatment was a one time oral
intubation following an eight day acclimation period. Clinical signs of toxicity- before dosing, 2hr post dosing, and daily
thereafter for two days. Body weights recorded prior to dosing and sacrifice. preparation of bone marrow smears made at
24 hr and 48 hr.
Immediately after sacrifice, marrow from both femurs of each animal was aspirated into a syringe of foetal bovine serum (FBS) then transferred to a test tube containing FBS. Marrow samples were collected by centrifugation. The supernatant was removed before re-suspending the cell pellet in the remaining 1-2 drops of FBS. A small drop was spread onto an appropriately labelled slide. Three slides per animal were prepared and fixed in absolute methanol. The slides were then stained in acridine orange in phosphate buffer for 3 minutes.
METHOD OF ANALYSIS: using incident light fluorescence microscopy. Only cells with good morphology and staining
were counted. Color used to distinguish PCEs (reddish orange) from NCEs (dark green). PCEs (2000/animal) were
evaluated for the presence of micronuclei. Unit of scoring was the micronucleated cell; therefore, PCEs with more than 1
micronucleus wre scored as a single MNPCE. - Evaluation criteria:
- Bone marrow smears were examined using incident light fluorescence microscopy. Only cells with good morphology and staining were counted. Colour was used to distinguish PCEs (reddish orange) from NCEs (dark green). PCEs (2000/animal) were evaluated for the presence of micronuclei (round, bright yellow fluorescing bodies). The unit of scoring was the micronucleated cell; therefore, PCEs with more than 1 micronucleus were scored as a single MNPCE. Micronucleated NCEs were counted in each optic field while scoring the 2000 PCEs. Additionally, the number of PCEs among 1000 erythrocytes was recorded for each animal.
- Statistics:
- For a test substance to be judged negative, no statistically significant increases in MNPCEs above the concurrent vehicle control values can occur at any dose level or sampling time.
In order for a test substance to be judged positive, statistically significant increases in MNPCEs above concurrent vehicle control values must be observed at more than one sampling time, or in both sexes.
Data for the proportion of MNPCEs among 2000 PCEs and the proportion of PCEs among 1000 erythrocytes (MNPCE and
PCE frequency, respectively)were transformed prior to analysis using the arcsine square root function. This transformation
is appropriate for proportions since the distributionof the transformed data more closely approximates a normal distribution
than does the non-transformed proportion. Transformed data for PCE andMNPCE frequencies were analyzed separately
for normality of distribution and/or equality of variance using the Shapiro-Wilk and Bartlett's or variance ratio tests,
respectively. Results indicated that the transformed values for PCE frequency were not normally distributed. Therefore,
nonparametric statistics were performed using nontransformed data (Kruskal-Wallis, Dunn's and Mann-Whitney U tests).
The transformed values for MNPCE frequency were normally distributed and had equal variance. Therefore, parametric
statistics were performed using transformed data ( ANOVA and Dunnett's test). Weight change data were assumed to be
normally distributed and were analyzed by ANOVA. Data from each sex and sacrifice time were analyzed separately, and
individual group comparisons to the controls were made. The animal was considered the experimenta unit. All analyses
were conducted at a significance level of 5%. Positive indicator data were analyzed separately
Results and discussion
Test results
- Sex:
- male/female
- Genotoxicity:
- negative
- Remarks:
- no statistically significant increases in micronucleated PCEs
- Toxicity:
- yes
- Remarks:
- systemic toxicity (lethargy, moribundity, abnormal gut) in highest dose groups (5/15 males and 2/13 females), and 1 female and 1 male died, no significant decreases in body weight
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose range:382-3147 mg/kg.
- Solubility: No data.
- Clinical signs of toxicity in test animals included abnormal gait, lethargy, ruffled fur, gasping, moribundity, pallor and/or
vocalization in most mice receiving 1588mg/kg or higher.
- Evidence of cytotoxicity in tissue analyzed: No data.
- High dose with and without activation: No activation used. 3147mg/kg.
- Other: 3 mice died following a 3147mg/kg dose, 3 were dead after a dose of 2353mg/kg, and one was dead after a dose
of 1588mg/kg.
RESULTS OF DEFINITIVE STUDY
- Induction of micronuclei (for Micronucleus assay): No statistically significant increases.
- Ratio of PCE/NCE (for Micronucleus assay): 0.78-1.45 for female and 0.86-1.24 for males.
- Appropriateness of dose levels and route: Based on rangefinding study in male and female mice that looked at clinical
toxicity. Picked doses in which clinical toxicity would not be expected.
Any other information on results incl. tables
In the high dose group, clinical signs of reaction to treatment were apparent within 2 hours of dosing. Signs of lethargy, moribundity and/or abnormal gait were recorded for several males and females. Signs of lethargy and moribundity persisted for up to 48 hours after dosing. On the day following dosing 4 males and 2 females in the high dose group were found dead and a further one male and one female died on the following day. Mortalities were considered to be treatment-related.
There were no effects on bodyweight gains for any of the surviving mice dosed with glycolic acid. No clinical signs were noted for the positive control group. There were no statistically significant increases in MNPCE frequency in either male or female mice treated with glycolic acid.
Applicant's summary and conclusion
- Conclusions:
- Glycolic acid was non-mutagenic in the micronucleus test in vivo. The study and the conclusions which are drawn from it fulfill the quality criteria (validity, reliability, repeatability).
- Executive summary:
Glycolic acid was non-mutagenic in the micronucleus test in vivo. The GA 70% solution was found negative in the mouse micronucleus assay, showing no evidence of test compound induced clastogenicity or aneugenicity. The study was dosed up to the maximum feasible dose level (1600 mg/kg bodyweight) considering test substance related adverse toxic signs and mortality. The negative results are accompanied by an observable albeit not statistically significant depression in the proportion of PCEs/total erythrocytes in both male and male animals at 48 hrs, indicative of some marrow toxicity and thus showing that the test compound reach the target cells.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.